Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation.
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
/ pharmacology
Animals
Antibodies, Monoclonal
/ pharmacology
Antineoplastic Agents
/ pharmacology
CD8-Positive T-Lymphocytes
/ drug effects
CHO Cells
Cell Line
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cricetulus
Female
Humans
Inflammasomes
/ drug effects
Male
Membrane Proteins
/ metabolism
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Neoplasms
/ drug therapy
Xenopus laevis
/ metabolism
TMEM176B
cancer
dendritic cells
immune checkpoint blockers
inflammasome
ion channel
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
13 05 2019
13 05 2019
Historique:
received:
21
06
2018
revised:
20
02
2019
accepted:
10
04
2019
entrez:
16
5
2019
pubmed:
16
5
2019
medline:
15
2
2020
Statut:
ppublish
Résumé
Although immune checkpoint blockers have yielded significant clinical benefits in patients with different malignancies, the efficacy of these therapies is still limited. Here, we show that disruption of transmembrane protein 176B (TMEM176B) contributes to CD8
Identifiants
pubmed: 31085177
pii: S1535-6108(19)30198-9
doi: 10.1016/j.ccell.2019.04.003
pmc: PMC6521897
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Inflammasomes
0
Membrane Proteins
0
Tmem176B protein, mouse
0
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
71145-03-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
767-781.e6Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
J Leukoc Biol. 2010 Sep;88(3):507-15
pubmed: 20501748
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Nat Immunol. 2013 Jun;14(6):543-53
pubmed: 23644505
Lancet Oncol. 2017 Dec;18(12):e731-e741
pubmed: 29208439
Immunity. 2013 Jun 27;38(6):1142-53
pubmed: 23809161
Cell. 2018 Jul 26;174(3):716-729.e27
pubmed: 29961576
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Immunity. 2016 Oct 18;45(4):719-736
pubmed: 27760337
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Am J Transplant. 2014 May;14(5):1021-1031
pubmed: 24731243
Nature. 2016 Sep 22;537(7621):539-543
pubmed: 27626381
Trends Immunol. 2018 May;39(5):393-406
pubmed: 29452983
Nat Commun. 2016 Dec 23;7:13720
pubmed: 28008905
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11282-7
pubmed: 22733741
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
Am J Transplant. 2005 Sep;5(9):2143-53
pubmed: 16095493
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Cell Host Microbe. 2010 Dec 16;8(6):471-83
pubmed: 21147462
Nat Rev Drug Discov. 2018 Aug;17(8):588-606
pubmed: 30026524
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Immunol Cell Biol. 2016 Jan;94(1):11-23
pubmed: 25835430
Cancer Immunol Res. 2017 Feb;5(2):94-99
pubmed: 28093447
Cancer Cell. 2015 Apr 13;27(4):574-88
pubmed: 25873177
Cell. 2017 Nov 16;171(5):1110-1124.e18
pubmed: 29033128
Sci Rep. 2017 May 15;7(1):1892
pubmed: 28507328
J Immunol. 2011 Nov 1;187(9):4411-5
pubmed: 21948982
Cell. 2016 May 5;165(4):792-800
pubmed: 27153493
Mol Pharmacol. 1987 Mar;31(3):221-31
pubmed: 2436031